Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pacific Ketamine Institute is a private U.S. healthcare provider focused on ketamine-based treatment services for mental health and pain indications. The organization operates as a specialty ketamine clinic offering racemic ketamine intravenous infusion therapy and Spravato administration for patients with conditions including depression, post-traumatic stress disorder, anxiety, bipolar mood disorder, and chronic pain. Public materials describe the business as a Beverly Hills-launched treatment center led by pain management and anesthesiology physician Dr. Michael Steuer, with additional references to Santa Monica and a MidSouth-related entity structure. Rather than developing proprietary drugs, Pacific Ketamine Institute appears to commercialize physician-administered treatment services through clinic operations and patient care delivery.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pacific Ketamine Institute.